| A review of the available evidence for patients with type 2 diabetes mellitus (T2DM) suggests that good glycaemic control is an important factor in reducing the risk of diabetes-related complications such as cardiovascular (CV) events and hypoglycaemia |
| There is no difference in CV risk between sulfonylureas (SUs) and agents such as pioglitazone or linagliptin, according to recent large randomised controlled trials (ADVANCE, TOSCA.IT, CAROLINA) |
| The risk of hypoglycaemia varies between SUs, with the lowest rates reported for gliclazide, although absolute risk of hypoglycaemia is low for the class as a whole |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.